Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States

Journal of Managed Care Pharmacy

Volumn 19, Issue 3, 2013, Pages 237-246

  Langer, Jakob ^a   Hunt, Barnaby ^b   Valentine, William J ^b  

^a NOVO NORDISK INC   (United States)

^b Ossian Health Economics and Communications   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84878910673     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.3.237     Document Type: Article

References (31)

1. World Health Organization. Fact file: 10 facts about diabetes. Available at: http://www.who.int/features/factfiles/diabetes/facts/en/index.html. Accessed March 7, 2013.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and estimated for 2030. Diabetes Care. 2004;27(5):1047-53. Availabe at: http://care.diabetesjournals.org/content/27/5/1047.long. Accessed March 7, 2013.
3. International Diabetes Federation. IDF diabetes atlas, 5th ed. Available at: http://www.eatlas.idf.org/media. Accessed March 7, 2013.
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615. Available at: http://care.diabetesjournals.org/content/31/3/596.long. Accessed March 7, 2013.
5. Mazzola N. Review of current and emerging therapies in type 2 diabetes mellitus. Am J Manag Care. 2012;18(1 Suppl):S17-S26. Available at: http://www.ajmc.com/publications/supplement/2012/ACE005_12Jan_Glucose/ACE005_12jan_Mazzola_S17/6. Accessed March 7, 2013.
6. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-93. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa021778. Accessed March 7, 2013.
7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-91. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa0706245. Accessed March 7, 2013.
8. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care. 2008;31(8):1510- 15. Available at: http://care.diabetesjournals.org/content/31/8/1510.long. Accessed March 7, 2013.
9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79. Available at: http://care.diabetesjournals.org/content/35/6/1364.long. Accessed March 7, 2013.
10. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705.
11. Victoza (liraglutide [rDNA origin] injection), solution for subcutaneous use. Prescribing information. Novo Nordisk. December 13, 2012. Available at: http://www.novo-pi.com/victoza.pdf. Accessed March 7, 2013.
12. BYETTA (exenatide) injection. Prescribing information. Amylin Pharmaceuticals Inc. December 2011. Available at: http://documents.byetta.com/Byetta_PI.pdf. Accessed March 7, 2013.
13. Nauck MA, Hompesch M, Filipicazak R, Le TD, Zdravkovic M, Glumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutadide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006;114(8):417-23.
14. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus: the LEAD (liraglutide effect and action in diabetes)- 2 study. Diabetes Care. 2009;32(1):84-90. Available at: http://care.diabetesjournals.org/content/32/1/84.long. Accessed March 7, 2013.
15. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-81.
16. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-100. Available at: http://care.diabetesjournals.org/content/28/5/1092.long. Accessed March 7, 2013.
17. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-35. Available at: http://care.diabetesjournals.org/content/27/11/2628.long. Accessed March 7, 2013.
18. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin- 4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083- 91. Available at: http://care.diabetesjournals.org/content/28/5/1083.long. Accessed March 7, 2013.
19. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformintreated patients with type 2 diabetes. Diabetes Care. 2004;27(12):2874-80. Available at: http://care.diabetesjournals.org/content/27/12/2874.long. Accessed March 7, 2013.
20. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(5):2078-84. Available at: http://jcem.endojournals.org/content/89/5/2078.long. Accessed March 7, 2013.
21. Scott R, Herman G, Zhao P, Chen X, Wu M, Stein P. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPPIV) inhibitor, in the treatment of type 2 diabetes (T2D). Diabetes. 2005;54(Suppl 1):S10- S11. [Abstract]
22. Hanefeld M, Herman G, Mickel C, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetologia. 2005;48(Suppl 1):S287-S288.
23. Pratley RE, Nauck M, Bailey T, et al.; the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447-56.
24. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397-407. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2011.02656.x/full. Accessed March 7, 2013.
25. MEDI-Span. Price Rx. Walter Kluwers Health. Available at: http://www.medispan.com/drug-pricing-analysis-pricerx.aspx. Accessed March 7, 2013.
26. American Diabetes Association. Standards of medical care in diabetes- 2012. Diabetes Care. 2012;35(Suppl 1):S11-S63. Available at: http://care.diabetesjournals.org/content/35/Supplement_1/S11.long. Accessed March 7, 2013.
27. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268-78. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2009.02666.x/full. Accessed March 7, 2013.
28. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27(9):2262-65. Available at: http://care.diabetesjournals.org/content/27/9/2262.long. Accessed March 7, 2013.
29. Lee WC, Samyshkin Y, Langer J, Palmer JL. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012;15(Suppl 2):28-37.
30. Bergenstal RM, Forti A, Chiasson J, et al. Once weekly taspoglutide, a human GLP-1 analog, is superior to sitagliptin in improving glycaemic control and weight loss in patients with type 2 diabetes (T2D): results from the T-emerge 4 trial. Diabetes. 2010;59(Suppl 1):A16. [Abstract}
31. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-39.